Gemelli Biotech's Innovative Trio-Smart® Breath Test Featured in Multiple Research Studies at DDW 2025
RALEIGH, N.C.--(BUSINESS WIRE)--Gemelli Biotech and its technologies will be featured in several presentations at Digestive Disease Week® (DDW) 2025. These studies used Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane.
'We're excited to see Trio-Smart contributing to research that can help millions of people who suffer from the symptoms of IBS."
Share
The studies further validates the accuracy and utility of Trio-Smart and shows the significant cost savings that can result from its use in the diagnosis of SIBO (small intestinal bacterial overgrowth).
Research being presented includes:
An Integrative Approach to Improve 3-Gas Breath Tests Using Patient Symptom Profile by Machine Learning (5/3/25 12:30-1:30pm POSTER #Sa2030)
Real World Study of Three-Gas Breath Testing Nationwide and the Association With Symptoms (5/5/25 12:30-1:30pm POSTER #Mo1405)
Lactulose Breath Testing Is More Often Positive and Associated With Symptoms Compared to Glucose in a Nationwide Study of Kit-Based Three-Gas Breathing (5/6/25 12:30-1:30pm POSTER #Tu2015)
Low- And High-Dose Rifaximin Versus Low-Dose Rifaximin Combined With N-Acetylcysteine For Treating Diarrhea-Predominant Irritable Bowel Syndrome: A Double-Blind, Randomized Proof-Of-Concept Trial (5/5/25 4:00pm Session #4585, ROOM 24 (SDCC)
Matt Mitcho, CEO of Gemelli Biotech, said 'Our understanding of the gut microbiome has grown dramatically, largely driven by access to new and better research tools. Studies like these have never been done with breath testing for chronic GI complaints. They emphasize the validity and importance of measuring all three gases during breath testing.'
He also explained that, 'We're excited to see Trio-Smart contributing to research that can help millions of people who suffer from the symptoms of IBS. Our unique ability to detect hydrogen sulfide coupled with our high-precision hydrogen and methane measurement makes Trio-Smart a powerful research tool. We have been talking with oncologists and other researchers about using our breath test in the lab and have even heard from rheumatologists and other inflammation-focused researchers about our blood test for markers of post-infectious IBS.' Matt continued, 'We look forward to continuing our ongoing work with the Medically Associated Science and Technology (MAST) program at Cedars-Sinai and to contributing to research in other areas as well.'
About Gemelli Biotech
Gemelli Biotech develops and distributes at-home, mail-in precision diagnostics for diseases of the gut microbiome. Our mission is to leverage leading biological discoveries related to the microbiome to provide non-invasive, easy-to-understand diagnostics. This enables clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including IBS, SIBO, IMO, and ISO. Our products include the Trio-Smart® breath test that measures levels of hydrogen, methane, and hydrogen sulfide; the IBS-Smart® blood test that measures validated biomarkers of IBS, anti-CdtB, and anti-vinculin, offering a positive diagnostic strategy for patients with IBS symptoms; and the Trio-Smart Malabsorption breath test that helps identify carbohydrate intolerances after lactose, fructose, or sucrose consumption.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
Cerus Corporation Celebrates World Blood Donor Day 2025
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, 'Give blood, give hope: together we save lives' is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and expand donor eligibility, helping more people give, and more people receive the transfusions they need. The Company salutes the individuals, communities, and countries working together to make blood safety and availability a reality. 'A safe and reliable blood supply remains a cornerstone of every effective healthcare system around the globe, and one that would not be possible without the countless individuals that donate their time and blood. World Blood Donor Day is an opportunity to thank these individuals and to raise public awareness of the ongoing need for additional blood donations,' said Obi Greenman, Cerus' President and Chief Executive Officer. 'I am proud that Cerus is leading the development of pathogen reduction technologies for transfused blood components to help enable our blood center customers to deliver safe and effective blood components to patients.' According to the World Health Organization (WHO), more than 118.5 million blood donations are collected annually around the world, with 40% of these donations collected in high-income countries that account for only 16% of the global population. A wide variety of patients regularly receive blood transfusion, including cardiovascular surgery, transplant surgery, massive trauma, cancer, obstetric, and childhood anemia patients. 1 In recognition of World Blood Donor Day, Cerus hosted a blood drive earlier this week at its company headquarters and encourages everyone to participate in supporting blood product availability in their local communities. 1. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Yahoo
7 hours ago
- Yahoo
Cerus Corporation Celebrates World Blood Donor Day 2025
CONCORD, Calif., June 13, 2025--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) is proud to announce its celebration of World Blood Donor Day 2025. In 2005, the World Health Assembly designated June 14th as World Blood Donor Day to recognize and thank blood donors across the world for their important contributions to the global blood supply. This year's theme, "Give blood, give hope: together we save lives" is a reminder that hope is something we can all share. Cerus is proud to promote blood safety and expand donor eligibility, helping more people give, and more people receive the transfusions they need. The Company salutes the individuals, communities, and countries working together to make blood safety and availability a reality. "A safe and reliable blood supply remains a cornerstone of every effective healthcare system around the globe, and one that would not be possible without the countless individuals that donate their time and blood. World Blood Donor Day is an opportunity to thank these individuals and to raise public awareness of the ongoing need for additional blood donations," said Obi Greenman, Cerus' President and Chief Executive Officer. "I am proud that Cerus is leading the development of pathogen reduction technologies for transfused blood components to help enable our blood center customers to deliver safe and effective blood components to patients." According to the World Health Organization (WHO), more than 118.5 million blood donations are collected annually around the world, with 40% of these donations collected in high-income countries that account for only 16% of the global population. A wide variety of patients regularly receive blood transfusion, including cardiovascular surgery, transplant surgery, massive trauma, cancer, obstetric, and childhood anemia patients.1 In recognition of World Blood Donor Day, Cerus hosted a blood drive earlier this week at its company headquarters and encourages everyone to participate in supporting blood product availability in their local communities. 1. ABOUT CERUS Cerus Corporation is dedicated solely to safeguarding the world's blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit and follow us on LinkedIn. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. View source version on Contacts Tim Lee – Head of Investor RelationsCerus Corporation925-288-6128 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Breast Cancer Canada Applauds Federal Commitment to Modernize Preventive Health Guidelines
Inclusion of experts, patient voices, and equity-focused policy reflects priorities long championed by Breast Cancer Canada TORONTO, June 13, 2025--(BUSINESS WIRE)--Breast Cancer Canada proudly celebrates the federal government's response to the External Expert Review (EER) of the Canadian Task Force on Preventive Health Care, and the sweeping reforms it recommends to ensure preventive health guidance in Canada is more equitable, expert-informed, and responsive to real-world care. "These systematic changes will save lives," said Kimberly Carson, CEO of Breast Cancer Canada. "We commend Canada's Federal Health Minister Marjorie Michel for making this a priority so early in her mandate, and we thank former Health Minister Mark Holland for working so closely with Breast Cancer Canada during his tenure. This milestone reflects years of dedicated advocacy. Bringing expert voices into task force decision-making is a long-overdue step toward ensuring that both science and lived experience shape public policy for Canadians." The EER outlines recommendations, including stronger integration of subject matter experts, patient and public voices, and structured provincial input in guideline development. For Breast Cancer Canada and the REAL Canadian Breast Cancer Alliance—a national coalition of breast cancer experts—the report validates their persistent calls to reform how health guidance is developed and delivered in Canada. It also affirms that advocacy works: the federal government listened to patients and advocates calling for change. This report embodies the transformative shift Breast Cancer Canada has relentlessly advocated for: expert-led, patient-centred, and equity-driven care informed by Canadian data and research. It signals a new era in Canadian breast cancer policy, one grounded in a national commitment to access for all. "This report is a breakthrough," said Kimberly Carson, CEO of Breast Cancer Canada. "It recognizes that science and lived experience must work together to shape public health guidance. These recommendations reflect what Breast Cancer Canada, researchers, clinicians, and patients have been saying for years." Founded by Breast Cancer Canada in 2023, REAL Canadian Breast Cancer Alliance brings together leading clinicians, patient advocates and data from across the country to advance evidence-based, equitable, and patient-informed breast cancer care. REAL Alliance was established to ensure that the latest research reaches patients faster and to help establish equitable, national standards of care for breast cancer. Breast Cancer Canada is actively addressing the critical gap in Canadian-specific data by collecting and analyzing breast cancer outcomes across all stages and subtypes, with a focus on race, age, and geographic location. "We are especially encouraged to see a formal shift toward expert engagement," said Shaniah Leduc, Chair of Breast Cancer Canada's Board of Directors. "Guidelines that impact patient outcomes must include disease-specific expertise. It's not just about input—it's about equity and access. Science moves quickly, and lives are affected when guidelines lag behind. A commitment to living guidelines ensures Canadians benefit from the most current knowledge in real-time." "As someone whose survival depended on timely diagnosis and access to targeted treatment, I know firsthand the power of evidence-based care," said Kim MacDonald, breast cancer survivor and advocate with Breast Cancer Canada. "The recommendations released today are long overdue. Including expert insight and patient experience in national health guidance isn't just the right thing to do—it's what saves lives. My story could have ended differently without access to the testing and treatment I needed. Every Canadian deserves equity and access." As the report notes, current guideline development in Canada is fragmented and often lacks the flexibility to reflect provincial realities or incorporate diverse forms of knowledge. The recommendations call for a pan-Canadian coordination hub and better integration with provincial screening programs, quality councils, and implementation bodies. "When evidence, expert insight, and lived experience come together, patients benefit," Carson added. "We look forward to seeing these recommendations put into action and continuing our role in ensuring breast cancer care is equitable, evidence-based, and patient-informed." Key Takeaways from the External Expert Review of Canada's Preventive Health Guidelines: Formal inclusion of clinical subject matter experts in the Task Force's working groups to strengthen evidence interpretation and disease-specific expertise Structured engagement of patients and community members, particularly from underrepresented groups, to bring real-world lived experience into national guideline development Equity-focused topic selection and public accountability, ensuring preventive guidance addresses the realities of all people in Canada, especially those from equity-denied populations Contextualizable and coordinated guidelines, enabling provinces and territories to implement evidence-based recommendations in a way that fits their own systems and structures A phased transition to living guidelines, so recommendations keep pace with science and practice in real-time Breast Cancer Canada remains a committed partner in this modernization effort, with ongoing investments in personalized screening research and the REAL Alliance—a multi-disciplinary expert body established to accelerate breast cancer progress through national collaboration. Breast Cancer Canada is a national charity dedicated to saving lives through science. Focused exclusively on breast cancer research, Breast Cancer Canada funds programs that advance earlier detection, better treatment, and improved outcomes for everyone affected by the disease. For more information, visit About Breast Cancer Canada Breast Cancer Canada is a national charity focused exclusively on breast cancer research, education, and awareness. Dedicated to advancing science that leads to earlier detection, more precise treatments, improved access to care, and better outcomes, the organization ensures that lived experience is reflected in research priorities. With no government funding, all progress is made possible through the generosity of donors. To learn more, visit About REAL Canadian Breast Cancer Alliance REAL (Research Excellence + Active Leadership) Canadian Breast Cancer Alliance is a national coalition of clinical and academic experts driving improvements in breast cancer care. Formed in 2023 by Breast Cancer Canada, REAL Alliance produces annual evidence-based clinical recommendations through a structured, consensus-driven process that reflects the latest in research and innovation. REAL Alliance is committed to advancing national standards of care and ensuring all Canadians benefit from the best available science. To learn more, visit View source version on Contacts Media Megan DunscombeBreast Cancer Canadamdunscombe@
